Core Points - The article highlights the issue of "yin-yang pricing" in pharmacies, where the same cold medicine costs 17 yuan for non-insured individuals and 31 yuan for insured individuals, indicating a significant price discrepancy [1] - The practice of "yin-yang pricing" undermines the security of the medical insurance fund and damages the interests of insured individuals, leading to a loss of public trust in the medical insurance system [1] - A recent notice has been issued to strengthen monitoring and handling of "yin-yang pricing" in designated retail pharmacies, emphasizing the need for strict investigation and punishment [1] Group 1 - The article discusses the reasons behind pharmacies engaging in "yin-yang pricing," including the pressure to alleviate operational costs and the lack of transparency in drug pricing [1] - It emphasizes that the medical insurance fund is crucial for the public and should not be infringed upon, calling for a collaborative effort from various departments to combat this issue [1] - The article suggests that punitive measures such as interviews, suspension of medical insurance settlements, and termination of medical service agreements should be implemented against pharmacies practicing "yin-yang pricing" [1] Group 2 - The article proposes preventive measures to address the "yin-yang pricing" phenomenon, including the use of technology to create a comprehensive supervision network through drug price comparison apps and traceability codes [2] - It advocates for the public display of inquiry and reporting channels in pharmacies to enhance community oversight [2] - The article concludes that the qualification for medical insurance designated pharmacies should be viewed as a responsibility for honest operation, and that punishing "yin-yang pricing" will lead to fairer and more transparent drug purchasing for the public [2]